🇺🇸 FDA
Patent

US 7038060

Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one

expired A61PA61P1/02A61P31/04

Quick answer

US patent 7038060 (Synthesis of 2-butyl-3-(2′-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Apr 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue May 02 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P1/02, A61P31/04